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Abstract The SRP~14-9 fusion protein, which can functionally 
replace the SRP9/14 heterodimer in the mammalian signal 
recognition particle (SRP), has been crystallized using the vapor 
diffusion method. Four different crystal forms were grown. 
SRP~14-9 form IV crystals belong to the space group P4122! 
P4322 with cell parameters a = b = 69.7 A, c = 95.7 A, 
¢z = [~ = ~/= 90% A complete data set to 2.8 A resolution with 
an Rsym on intensities of 7.0% was collected on a single flash- 
frozen crystal. 
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I. Introduction 
The mammalian signal recognition particle (SRP) is a cyto- 
plasmic ribonucleoprotein particle (RNP) that plays an essen- 
tial role in the targeting of secretory and membrane proteins 
to the rough endoplasmic reticulum (RER) (for recent reviews 
see [1,2]). Targeting occurs co-translationally and transloca- 
tion across the RER membrane begins before polypeptide 
synthesis is complete [3-5]. The SRP acts in three distinct 
ways [6]: it binds the signal sequence of the nascent polypep- 
tide to be translocated [4,6,7], which is exposed on the surface 
of the translating ribosome [8,9]; it temporarily retards the 
nascent polypeptide from further elongation [6,10,11]; and it 
mediates docking of the SRP-ribosome-nascent polypeptide 
chain complex to the RER membrane via the heterodimeric 
SRP receptor. With the engagement of this machinery, the 
SRP is detached and recycled, and co-translational transloca- 
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tion proceeds [12-14]. GTP hydrolysis plays an important role 
in the SRP cycle, one SRP protein and both subunits of the 
SRP receptor containing G-domains [2,15]. SRP is not re- 
stricted to eukaryotes; SRP-related particles and SRP recep- 
tor-related molecules are found ubiquitously and may func- 
tion in protein translocation i every living organism [16-18]. 
The mammalian SRP is an 11S cytoplasmic ribonucleopro- 
tein particle which consists of six polypeptides and a single 
RNA molecule (7S RNA in eukaryotes) [19,20]. The polypep- 
tides are named according to the apparent molecular masses 
(in kDa) of the canine proteins: SRP9, SRP14, SRP19, 
SRP54, SRP68, and SRP72. SRP54, which contains a GTP- 
binding domain, is the signal sequence binding protein and 
requires SRP19 for efficient binding to SRP RNA. Similarly 
SRP72 incorporation into SRP requires prior binding of 
SRP68 to SRP RNA. 
In vitro studies show mammalian SRP9 and SRP14 pro- 
teins form a tight heterodimer SRP9/14 in the absence of SRP 
RNA and bind specifically to a region of the SRP RNA which 
includes both the 3' and 5' ends [21]. The part of SRP com- 
prising SRP9/14 complexed with RNA forms a distinct struc- 
tural domain known as the Alu domain due to the homology 
of the RNA sequences with the so-called Alu family of repe- 
titive DNA sequences and the small cytoplasmic Alu RNAs 
(scAlus) [22]. SRP9/14, when bound to the Alu region of SRP 
RNA, forms a stable complex (Ka <- 0.1 nM) and causes an 
allosteric hange in the SRP RNA conformation [23]. The Alu 
domain of SRP mediates the specific pause(s) or arrest in the 
synthesis of nascent ER-targeted proteins whose signal se- 
quence has been bound by SRP54 [16]. Both the mechanism 
and the functional rationale for the elongation arrest activity 
are unknown although it is hypothesized that the mechanism, 
before docking with the translocation machinery, prevents 
translation termination and disengagement from the ribo- 
some. 
Primary sequences for several eukaryotic SRP9 and SRP14 
proteins have been characterized [24]. No known RNA bind- 
ing motif has been detected in the sequences. It is possible that 
SRP9/14 might possess a new RNA binding motif which may 
be generated upon heterodimerization si ce neither protein 
alone binds specifically to SRP RNA. Recently, it has been 
shown that human SRP9/14 in vivo [7], and SRP14 in vitro 
[25] can associate as complexes with scAlu RNA in so-called 
Alu particles. Furthermore, the human SRP14 is larger than 
its murine counterpart, his difference being due to a C-term- 
inal alanine/threonine-rich extension [25]. 
SRP9 can be highly over-expressed in Escherichia coli and is 
stable after purification [26]. SRP9 crystallization is described 
in the accompanying paper (Doubli6 et al.). On the other 
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hand, expression levels of SRP14 are poor and the protein is 
unstable. For structural and functional studies a fusion pro- 
tein, denoted SRPOl4-9, has been constructed which mimics 
the SRP9/14 heterodimer [26]. SRPOl4-9 is a single polypep- 
tide over-expressed in Escherichia coli, which can be purified 
to homogeneity and which is significantly more stable than the 
SRP9 and SRPI4 proteins alone. The SRPOl4-9 gene con- 
tains in its 5' region a sequence coding for the peptide 
MASMTGGQQMGRIPGNSPR (a cloning remnant) fol- 
lowed by the complete coding sequence of the mouse SRP14 
(110 amino acid residues and has a molecular weight of 12.5 
kDa) followed by a linker sequence of 51 base pairs and the 
complete coding sequence of the mouse SRP9 (86 amino acid 
residues and has a molecular weight of 10.2 kDa). The linker 
sequence ncodes 17 amino acids that contain the well char- 
acterized epitope ( -EQKLISEED)  for the monoclonal anti- 
body against the human Myc protein. The complete 
SRPOl4-9 fusion protein contains 232 amino acid residues 
and has a molecular weight of 26.7 kDa. 
SRP~14-9 can functionally replace the SRP9/14 heterodi- 
meric subunit in the SRP. It binds SRP RNA and functions in 
elongation arrest and release of elongation arrest without loss 
of activity compared to the native SRP9/14 heterodimer [26]. 
Two constructions of the fusion protein SRPOl4-9 and 
SRPO9-14, differing in the order of arrangement of SRP9 
and SRP14 in the polypeptide, have been shown to be equally 
active, indicating that the free N- or C-termini in either pro- 
tein, SRP9 or SRP14, are not essential structural elements in 
the function of the SRP9/14 heterodimer in the SRP. The 
over-expressed SRPq~14-9 greatly facilitates the structural 
and functional analysis of SRP9, SRP14, heterodimer SRP9/ 
14 and their interactions with SRP RNA.  
In this and the accompanying paper we describe the crystal- 
lization of SRPq~14-9 and SRP9, this being the first report of 
crystals of components of the mammalian SRP. Whereas 
many functional and biological aspects of SRP are under- 
stood, detailed structural information is completely lacking. 
The crystal structure of SRPOl4-9 will provide information 
about protein/protein and protein/RNA interactions as well as 
being the first step to understand the structural basis of the 
SRP Alu domain mediated elongation arrest. 
2. Materials and methods 
2.1. Expression and purification of the SRP~14-9 fusion protein 
Mouse SRPqbl4-9 fusion protein was cloned in pET3c expression 
vector and over-expressed in Escherichia eoli BL21/IysS [26]. 
Bacteria were grown in LB medium containing 50 p.g/ml of ampi- 
cillin in an 18 liter fermenter at 37°C. SRP~ 14-9 protein synthesis was 
induced with 0.8 mM isopropyl-13-o-thiogalactopyranoside (IPTG) at 
OD600=0.6 for 3 h. The cells were harvested by centrifugation and 
frozen in aliquots at -80°C. 5 g of cells were suspended in 15 ml of 50 
mM TRIS-HC1 pH 7.5, 10 mM MgC12, 10 mM [5-mercaptoethanol, 
10% glycerol, 1.0 mg of DNase, 500 p_M Pefabloc and the NaC1 
concentration was adjusted to 250 mM. Cells were lysed in a French 
press (1000 psi) after which 10 mM EDTA was added. The lysate was 
clarified by centrifugation at4°C for 20 min at 15 000 × g. 0.2% Poly- 
min P was added to the supernatant, incubated on ice for 15 min, then 
centrifuged at 4°C for 15 min at 12000×g. 
The supernatant was loaded on a heparin column (two sequential 
Bio-Rad 5 ml columns) equilibrated with buffer A (250 mM NaC1, 10 
mM Tris-HCl pH 7.5, 10 mM [3-mercaptoethanol and 1.0 mM 
EDTA). SRPqbl4-9 protein was eluted with a 60 ml gradient from 
buffer A to buffer B (1.0 M NaC1, 10 mM Tris-HC1 pH 7.5, 10 mM 13- 
mercaptoethanol and 1.0 mM EDTA). SRP~14-9 protein containing 
fractions were collected and precipitated with 70% saturated ammo- 
nium sulfate, incubated for 4 h on ice, then centrifuged at 15 000 x g 
for 20 min. 
The protein pellet was dissolved in 200 mM NaCI, 50 mM sodium 
phosphate pH 7.5, 10 mM 13-mercaptoethanol, 1.0mM EDTA and 
500 l.tM phenylmethylsulfonyl fluoride (PMSF) then dialyzed against 
the same buffer overnight at 4°C. The protein was loaded on a Mono- 
S HR5/5 column (Pharmacia-FPLC system) equilibrated with buffer C 
(200 mM NaC1, 50 mM Na/K PO4 pH 7.5). SRP~14-9 protein was 
eluted with a 20 ml linear NaC1 gradient from buffer C to buffer D 
(500 mM NaC1, 50 mM Na/K PO4 pH 7.5) and precipitated with 70% 
saturated ammonium sulfate as mentioned above. 
Pure SRP~14-9 protein was dialyzed against 500 mM (NH4)2SO4, 
10 mM Tris-HC1 pH 8.0 or against 500 mM Na/K PO4 pH 7.5 at 4°C 
then concentrated to 10 mg/ml using Centricon-10 concentrators. 
2.2. Crystallization procedures 
Initial crystallization conditions were obtained using incomplete 
factorial designs [27] and optimized using response surface experi- 
ments [28,29]. The crystallization conditions utilized various precipi- 
tants such as sulfates, phosphates, polyethylene glycols (PEGs) and 2- 
methyl-2,4-pentanediol (MPD), with concentrations ranging from 300 
mM to 2.9 M; various buffers such as acetate, citrate, MES, cacody- 
late, BICINE, HEPES, Tris, borate and CAPS, in their respective pH 
ranges from pH 4.0 to pH 11.0, in the concentration range from 20 
mM to 200 mM; a wide range of salts such as ammonium, calcium, 
lithium, magnesium, manganese, potassium and sodium in the con- 
centration range from 500 ~tM to 50 mM; and a number of additives 
or detergents such as n-octyl-13-D-glucopyranoside, dimethyl sulfoxide, 
glycerol, isopropyl alcohol, Nikkol and MPD, in the percentage range 
of 0.1% to 10%. 
The crystallization trials applied the hanging drop vapor diffusion 
method on silicanized glass cover slides in Linbro plates. Drops con- 
tained 2 ~tl of protein solution at 5-10 mg/ml and were mixed with 
equal volumes of reservoir solution and allowed to equilibrate against 
1.0 ml of reservoir solution at 4°C or 22°C. 
3. Results and discussion 
Crystallization conditions were found using an incomplete 
factorial design [27]. A crystallization data base [30] was 
searched for conditions used for ribosomal proteins, which 
are also small, basic, RNA binding proteins. The data base 
Table 1 
Native SRPO14-9 data 
30.0-2.80 ,~ resolution 2.95-2.80 A resolution shell 
Number of observations (I/gI>l) 31 918 4293 
Number of unique observations 5 798 755 
Average I1~I 6.4 2.7 
Completeness 94.5% 94.4% 
Percentage I/~I> 3 86.0% 67.1% 
Multiplicity 5.5 5.3 
Rsyra[~l(l)_<l)l]]~(l) 7.0% 28.0% 
aData were collected at the MAD Beamline: BL19 (D-14) at the ESRF using 0.927 A radiation. Data were collected on a single flash-frozen 
crystal at 100 K with a crystal-to-film distance of 420 mm on a 30 cm Mar Research image plate. Forty-two contiguous 1.5 ° oscillation 
rotation images were collected to 2.8 A resolution followed by 22 2.0 ° oscillation rotation images collected to 4.0 A resolution. 
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search showed that the ribosomal proteins in the data bank 
had been crystallized using sodium potassium phosphate, am- 
monium sulfate, or MPD, at a pH ranging from 7.2 to 8.5. 
The initial incomplete factorial experiments gave rise to two 
crystal forms: crystal form I grown in ammonium sulfate and 
PEG at pH 6.5, and crystal form III, grown using sodium 
potassium phosphate at pH 7.5, and MPD as an additive. 
The crystal form I of SRPOl4-9 was grown mixing high 
molecular weight PEG and ammonium sulfate as precipitants 
in hanging drop vapor diffusion experiments at room tem- 
perature. This precipitant mixture formed a solvent front 
where nucleation took place and sustained crystal growth oc- 
curred. During crystal growth, the crystals descended from the 
solvent front to a resting position at the bottom of the drop 
where further growth occurred. The reservoirs contain 28- 
32% PEG 8000, 200 mM (NH4)2SO4, 100 mM MES-KOH 
pH 6.5, 1.0 mM NaNz and 100 ~tM PMSF. Addition of 
dithiothreitol (DTT) was found to prevent crystallization. 
These crystals were difficult to reproduce and difficult to ma- 
nipulate. When harvesting crystals, difficulties ensued when 
the cover slide was inverted. The equilibrated rop went 
from a solvent front stable state to a turbulent, whirlpool- 
like environment of mixing solutions causing the crystal to 
be spun about the drop, rapidly dissolving or damaging the 
crystal. Applying other methods, such as sitting drop or ca- 
pillary crystallization techniques, resulted in poor quality crys- 
tals or no observed crystal nucleation. 
A second crystallization condition (crystal form II) grew in 
30-34% saturated ammonium sulfate, 50 mM MES-KOH pH 
6.0 and 1.0 mM NaN3, at room temperature. These crystals 
were not consistently reproducible and were difficult to man- 
age due to crystal size and fragility. No data has been col- 
lected on these crystals. 
For form I and form II SRPOl4-9 protein crystals, the 
average crystal dimensions were 50 × 50 x 30 ~tm a and crystals 
appeared after approximately 1 month. Form I crystals be- 
long to the tetragonal space group oI4(n) with unit cell para- 
meters a = b = 128.6 A,, c = 172.1 A, ~ = 13 = ~'= 90 ° and a 
unit cell volume of 2.83x 106 ,~3. The unit cell volume is 
consistent with the presence of 4 molecules per asymmetric 
unit corresponding to a specific volume Vm = 3.48 Aa/Da 
and solvent content of 65% [31]. X-ray diffraction experiments 
Fig. 1. Photograph of bipyramidal SRP~14-9 crystals. Typical drop 
showing SRPOl4-9 protein crystals with average dimensions 
150 x150 x 300 ~m a with single (NH4)2HPO4 salt crystal in back- 
ground. 
Native 
soluble Native 
Marker protein Crystal 
1 2 3 4 
Fig. 2. Photograph of a silver stained PAGE-SDS gel, showing 
SRP~bl4-9 washed and dissolved crystals (lane 4) and native soluble 
SRP~bl4-9 protein (lane 3). The bands migrate equally in gel indi- 
cating no degradation of SRP~14-9 into SRP9 or SRP14. 
on these crystals howed diffraction beyond 3.2 A. resolution. 
Crystals were extremely X-ray sensitive and suffered severe 
radiation damage after several exposures. Due to this con- 
straint, effective cryoprotectants for cryogenic experiments 
(100 K) were screened. A buffered solution of 30% glycerol 
mixed with 30% saturated ammonium sulfate acted as an 
effective cryoprotectant. An 80% complete data set to a reso- 
lution of 4.0 A with an Rsym on intensities of 7.2% was col- 
lected from a single flash-frozen crystal (100 K) on a MAR 
Research image plate at the ESRF-Beamline 19 (D-14). 
Due to the problems of crystal reproducibility, size and 
handling, other crystallization conditions were sought. The 
initial incomplete factorial experiment revealed that 
SRP~14-9 can be crystallized with the morphology of small 
rectangular plates (crystal form III) using sodium potassium 
phosphate as a precipitant. The crystals diffracted beyond 3.3 
A resolution but were not reproducible. Further precipitant 
gradients were used to screen for a reproducible crystallization 
condition using various phosphate mixtures. Mixtures of dis- 
odium hydrogen/monosodium dihydrogen/dipotassium hydro- 
gen/monopotassium dihydrogen phosphates were used as both 
precipitants and buffers. This phosphate mixture combined 
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with 2% MPD and 1.0 mM NaNa yielded square-base pyra- 
midal or bipyramidal crystals (crystal form IV) after 10-12 
days with typical dimensions of 150 × 150 × 300 I.tm a. 
The conditions for growing form IV crystals consist of a 
reservoir of 1.6-2.2 M Na2H/NaH2/K2H/KH2 PO4 mixture at 
pH 7.5, 2% MPD and 1.0 mM NaN3 at 4°C. The protein 
solution contains 500 mM (NH4)2SO4 and 10 mM Tris-HC1 
pH 8.0. The ammonium sulfate is necessary to keep the pro- 
tein soluble. As expected, upon mixing with the reservoir so- 
lution, (NH4)2HPO4 crystals are formed, altering both the 
soluble sulfate and soluble phosphate concentrations in the 
drop. Formation of form IV crystals is preceded by growth 
of a large (NH4)zHPO4 crystal, followed shortly by the nu- 
cleation and growth of SRP~14-9 protein crystals (Fig. 1). 
This procedure is reproducible. 
A native SRPOl4-9 crystal taken from its mother liquor in 
a hanging drop was washed and dissolved then run on a 
PAGE-SDS gel alongside soluble protein (Fig. 2). The silver 
stained gel shows that all three samples migrate equally as 
single bands, indicating no degradation i to SRP9 or SRP14 
proteins. 
Changes in pH alter the morphology of the crystals such 
that at pH 5.0 they grow as elongated pyramids, whereas at 
pH 7.5 they are bipyramidal. A suitable cryoprotectant for 
these crystals consists of 2.3-2.7 M Na2H/NaH2/K2H/KH2 
PO4 mixture at pH 7.5 and 20-30% MPD. 
X-ray diffraction experiments on flash-frozen crystals in a 
cold stream of nitrogen at 100 K showed diffraction beyond 
2.3 A resolution. The crystals belong to the tetragonal space 
group P4122/P4a22 with cell parameters a = b = 69.7 ,~,, 
c=90.7 A, ¢x=13 =Y =90 ° and a unit cell volume of 
4.65×105 .~a. This is consistent with one molecule of 
SRP~14-9 per asymmetric unit, Vm = 2.28 A3/Da and solvent 
content of 46%. 
A complete native data set to a resolution of 2.8 A was 
collected on a single flash-frozen crystal on a Mar Research 
image plate detector at the ESRF-Beamline 19 (D-14). Images 
were collected with an oscillation range of 1.5 ° for a data set 
to 2.8 A resolution and of 2.0 ° oscillations for a low resolu- 
tion data set to 4.0 ,~. The images were auto-indexed and 
intensities integrated using DENZO [32]. Data were scaled 
and merged using the CCP4 program package [33]. The over- 
all Rsy m of intensities was 7.0%, with a redundancy of 5.5 to 
2.8 A (Table 1). 
Selenomethionyl SRPqbl4-9 has been overexpressed, puri- 
fied and crystallized and will be used as a derivative in order 
to solve the phase problem either by multiple isomorphous 
replacement (MIR) or multiwavelength anomalous diffraction 
(MAD) methods. 
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